Biohaven announced plans to initiate pivotal clinical trials mid-2026 for its novel protein degrader therapies targeting IgA nephropathy and Graves' disease. The company expects topline results in the second half of 2026 from its epilepsy program using a selective Kv7 ion channel activator and from a Phase 2 obesity study with a myostatin-activin pathway inhibitor. Additional progress includes ongoing trials in early Parkinson's disease and advanced endometrial cancer, with no major safety issues reported. Biohaven reported a reduced net loss in Q1 2026 and maintains a strong cash position of approximately $352 million, positioning it well for upcoming milestones and continued development across its neuroscience, immunology, and oncology pipeline.
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
BrewDog, part of Tilray Brands, is rolling out a major summer campaign across the UK tied to the global football tournament. The campaign features a "Win a Year of Beer" contest with special cans hidden in over 2.8 million packs at major retailers, p...
Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, announced it will present at two upcoming investor conferences: William Blair’s Growth Stock Conference on June 2 and Jefferies Global Healthcare Conf...
G-III Apparel Group announced a quarterly cash dividend of $0.10 per share, payable on July 8, 2026, to shareholders of record as of June 22, 2026. This dividend reflects the company's ongoing commitment to returning value to its investors. G-III is ...
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
